Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 13144Neoplasms 10492Carcinoma, Non-Small-Cell Lung 6878Prostatic Neoplasms 6276Colorectal Neoplasms 5950Lung Neoplasms 5110Multiple Myeloma 3579Pancreatic Neoplasms 3564Leukemia, Myeloid, Acute 3512Neoplasm Metastasis 3511Carcinoma, Hepatocellular 3277Ovarian Neoplasms 3173Melanoma 3142Stomach Neoplasms 3058Lymphoma 2984Head and Neck Neoplasms 2608Recurrence 2557Precursor Cell Lymphoblastic Leukemia-Lymphoma 2500Leukemia 2362Colonic Neoplasms 2328Brain Neoplasms 2317Lymphoma, Non-Hodgkin 2269Uterine Cervical Neoplasms 2193Rectal Neoplasms 2192Glioblastoma 2018Leukemia, Lymphocytic, Chronic, B-Cell 1992Carcinoma, Renal Cell 1915Squamous Cell Carcinoma of Head and Neck 1880Lymphoma, Follicular 1851Esophageal Neoplasms 1801

Interventions

Radiotherapy 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-Negative Locally Advanced Breast Cancer × Clear all
NCT06908668 2025-04-03

Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy With or Without Radiotherapy as Neoadjuvant Treatment for HER2-Negative Locally Advanced Breast Cancer

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Not yet recruiting
170 enrolled
Breast

HER2-Negative Locally Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡